Gaselle bedrift 2016
Regenics AS one of Norways best performing companies 2016. Out of 264.000 registered businesess i Norway, 2481 companies (0.93 % of all) was selected in 2016 as "Gaselle" (gazelles) based on...
Regenics launch of new website
New website October 12th 2016!
Regenics attends BioMarine Business Convention in Oslo, Norway, October 19-21 2016
  BioMarine 2016 will focus on demonstrating the utility and feasibility of achieving a ‘full circle’ of the blue industry value chain. Extracting the ingredients and marine compounds produced during each...
3D printing Agreement with Chalmers, Sweden
Regenics AS, Norway enter into an agreement with Chalmers, Sweden  on exploring Vernex™ for 3D bioprinting.
DnB NXT October 19th, 2016 Oslo Innovation Week
Regenics AS presents at DnB NXT October 19th 2016
Succesfull placement of share issue August 2016
Regenics announces the succesfull private placement of new shares.
DnB Healtcare conference 2016
Regenics presented at DnB Healtcare conference 2016
Regenics publish data on vehicle for Vernex® at Drug Delivery meeting, France
Regenics publish data on its carrier/vehicle GMO to be used in the CE marking device for wound healing, 4th Congress of Drug Delivery, France. September 25-28, 2016
Regenics in press - Presentation in GENIALT from the Norwegian Biotechnology council
Press: The Norwegian Biotechnology Advisory Board monthly publication, GENIALT, October 2016, focus on Regenics roe technology. 
Data Protection Officer
Regenics appoints Chief Medical Officer as Data Protection Officer (Personvern ombud).
Vernex™ Medical device non-binding opinion by SLV
The Norwegian Medicines Agency (SLV) has on August 10th 2016 preliminary reviewed the regulatory status of Vernex™. 
TGA Sciences, Inc., US provides collagen data for salmon roe extract
Regenics releases salmon roe collagen boosting data in human fibroblasts performed by TGA Sciences, Inc., US.  
Regenics AS Annual Report 2015
Regenics post a first positive 2015 result with topline in excess of 4 mill NOK. 
Protocol from Extraordinary Annual Meeting July 11th 2016
July 11th 2016 Protocol from Extraordinary Annual Meeting July 11th 2016
Canadian National Patent 2016
Canadian National Patent issued to Regenics' technology on June 28, 2016.
Notice of Extraordinary Annual Meeting July 11th 2016
June 27th 2016 Notice of Annual Meeting July 11th 2016. The Annual Meeting 2016 will tale place at the Companys site Nycovn. 2, Oslo from 3 pm to 5 pm.

<<  <   Page 2 of 5   >  >>


June 5-6th 2017

Investor Conference Biotech-Medtech, at Stavanger Forum Oslo

Program (tbd)

March 9th 2017

Roundtable Conference in investing in Biotech, CEO Henrik Lund, moderator for the Event at Stavanger Forum Oslo

Program Roundtable Conference Stavanger

March 8th 2017

War on Cancer Nordics, CEO Henrik Lund participating in closing panel at the Economist Event in Oslo

Program Economist Event Oslo

December 15th 2016

DnB Healtcare Conference 2016, CMO Christian Clemm provides company update in the ventture session

Regenics presentation   

October 19-20-21 2016

Biomarine Convention, CEO Henrik Lund, participating at Convention in Oslo

Program Biomarine Business Conference

October 19th 2016

DnB Next at Oslo Innovation Week, CSO Gry Lønne, presenting Regenics Company update in Oslo

program DNB Next healthcare      Regenics presentation 

September 25-28 2016

At the 4th Congress on Innovation in Drug Delivery in Antibes, Regenics publish data on its carrier/vehicle GMO to be used in the CE marking device for wound healing.

Abstract 4th Congress on Innovation in Drug Delivery

October 22-24 2015

At the Joint Meeting of the European Tissue Repair Society (ETRS) and the Wound Healing Society (WHS), Regenics showed excellent and rapid wound healing of its wound healing device Vernex under development for CE-marking in 2018. In 2nd degree burn wounds Vernex provided rapid and complete reepitelialization of epidemal keratinocytes in human explanted skin. This represent a prooof of priciple for the utility of Vernex in human wound healing. 

Abstract 7th ETRS-WHS meeting

Regenics AS has developed a number of assays and techniques to study effects of various substances on skin cells both in vitroin vivo and in the clinic. Our focus is to develop products and techniques for therapeutic skin applications and to improve skin appearance.